Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 159

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 159
---
  
     174,349  
     412,604  
     264,504  
     84,401 
  
    Total lease cost 
    $454,205  
    $412,274  
    $871,266  
    $620,875  
    $195,286 

The
right-of-use asset, net for the operating lease was recorded in the consolidated balance sheets as follows:

    June 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Right-of-use
    assets, net 
    $1,072,950  
    $1,464,367 

The
operating lease liability for the operating lease was recorded in the consolidated balance sheets as follows:

     June 30,   December 31,      2025   2024      (Successor)   (Successor)   Operating lease liabilities, current  $934,310   $876,392   Operating lease liabilities, non-current   218,308    699,107   Total operating lease liabilities  $1,152,618   $1,575,499                Weighted-average remaining lease term of operating leases (in years)   1.25    1.75   Weighted-average discount rate for operating leases   9.60%   9.60% 

The
following table reconciles the undiscounted future minimum lease payments under the non-cancelable operating lease with terms of more
than one year to the total operating lease liabilities recognized on the Company’s balance sheet as of June 30, 2025:

Maturity
of the Company’s lease liabilities as of June 30, 2025 is as follows:

    2025 (remainder of year) 
    $499,929 
  
    2026 
     726,394 
  
    Total lease payments 
     1,226,323 
  
    Less: imputed interest 
     (73,705)
  
    Total lease liabilities 
    $1,152,618 

NOTE
8 – STOCKHOLDERS’ DEFICIT

Successor
Series A Convertible Preferred Stock

The
Company designated 12,580 shares of its authorized preferred stock as